Ray Tancredi of Walgreens Give an Outlook on Oncology Drugs, Other Standouts in the Pipeline
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been many oncology drug approvals. Over time, the number of approvals decreased each year.
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been good number of oncology drug approvals. Over time, number of approvals each year have dropped down from 22, to 19 and so on.
As of 2023, there's only been two drugs approved, Tancredi sees that "there could be three or four drugs approved before the end of this year, maybe more." There's a number of products in the pipeline that could get approved this year.
"So when it's all said and done at the end of 2023, you know, we could be in double digits again, for as far as approvals are concerned," he added.
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
